Azacitidine - TurnSole Biologics
Alternative Names: Azacitidin - TurnSole Biologics; TS-020Latest Information Update: 17 Feb 2022
At a glance
- Originator TurnSole Biologics
- Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action DNA methylation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 21 Jan 2022 TurnSole Biologics completes a phase-I/II trial in COVID-2019 infections (In adults, In the elderly, Adjunctive treatment) in Hungary (SC) (EudraCT2021-000516-37)